Dyne Therapeutics, Inc., headquartered in WALTHAM, Mass., announced on December 11, 2025, that it successfully closed an increased underwritten public offering. The offering consisted of 21,827,549 shares of common stock sold at a public price of $18.44 per share, with an additional 2,847,071 shares issued due to the underwriters exercising their option to purchase more shares. The total gross proceeds for Dyne from this offering amounted to about $402.5 million, excluding underwriting discounts, commissions, and offering expenses. The entirety of the shares in the offering were provided by Dyne. Dyne Therapeutics is a clinical-stage company specifically dedicated to enhancing functionality for individuals afflicted with genetically induced neuromuscular disorders.